Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial
(Adnkronos) – Trial meets all primary and secondary endpoints across pediatric population ages 2 and older ANNAPOLIS, Md. and MALAGA, Spain, May 4, 20232 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company
